ID   NCI-H3255
AC   CVCL_6831
SY   H3255; H-3255; H3255_DA; NCIH3255
DR   BTO; BTO:0006539
DR   EFO; EFO_0003123
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2882
DR   BioSample; SAMN03471808
DR   BioSample; SAMN10988059
DR   cancercelllines; CVCL_6831
DR   Cell_Model_Passport; SIDM00046
DR   ChEMBL-Cells; CHEMBL4295484
DR   ChEMBL-Targets; CHEMBL4296476
DR   Cosmic; 897734
DR   Cosmic; 903623
DR   Cosmic; 914952
DR   Cosmic; 1028937
DR   Cosmic; 1128245
DR   Cosmic; 1146914
DR   Cosmic; 2647633
DR   Cosmic-CLP; 1247873
DR   DepMap; ACH-000109
DR   DepMap; ACH-002137
DR   EGA; EGAS00001000978
DR   GDSC; 1247873
DR   GEO; GSM63349
DR   GEO; GSM108847
DR   GEO; GSM108848
DR   GEO; GSM253411
DR   GEO; GSM434297
DR   GEO; GSM794371
DR   GEO; GSM827356
DR   GEO; GSM1374743
DR   GEO; GSM1669833
DR   IARC_TP53; 28350
DR   IGRhCellID; H3255_DAGEO
DR   LiGeA; CCLE_545
DR   NCI-DTP; NCI-H3255
DR   PharmacoDB; NCIH3255_1108_2019
DR   PRIDE; PXD001548
DR   PRIDE; PXD002224
DR   PRIDE; PXD002556
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_6831
DR   PubChem_Cell_line; CVCL_6831
DR   Wikidata; Q54908036
RX   PubMed=11030152;
RX   PubMed=12759538;
RX   PubMed=16187286;
RX   PubMed=20215515;
RX   PubMed=20679594;
RX   PubMed=22961666;
RX   PubMed=26202522;
RX   PubMed=26361996;
RX   PubMed=26554430;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=29681454;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=31803961;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Caucasian.
CC   HLA typing: A*01:01,03:01; B*37:01,41:01; C*06:02,06:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-1G>A; ClinVar=VCV000634769; Zygosity=Unspecified; Note=Splice acceptor mutation (DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep membrane proteome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=3.63%; Native American=0%; East Asian, North=2.06%; East Asian, South=0%; South Asian=0%; European, North=59.85%; European, South=34.46% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-2882; true.
CC   Discontinued: DepMap; ACH-002137; true.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC; Cosmic-CLP; PubMed=20679594
ST   Amelogenin: X
ST   CSF1PO: 11,14
ST   D13S317: 11,13
ST   D16S539: 8
ST   D5S818: 11,12
ST   D7S820: 10,13
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 35
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=12759538; DOI=10.1159/000070299;
RA   Fujishita T., Loda M., Turner R.E., Gentler M., Kashii T.,
RA   Breathnach O.S., Johnson B.E.;
RT   "Sensitivity of non-small-cell lung cancer cell lines established from
RT   patients treated with prolonged infusions of paclitaxel.";
RL   Oncology 64:399-406(2003).
//
RX   PubMed=16187286; DOI=10.1002/ijc.21491;
RA   Garnis C., Lockwood W.W., Vucic E., Ge Y., Girard L., Minna J.D.,
RA   Gazdar A.F., Lam S., MacAulay C., Lam W.L.;
RT   "High resolution analysis of non-small cell lung cancer cell lines by
RT   whole genome tiling path array CGH.";
RL   Int. J. Cancer 118:1556-1564(2006).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20679594; DOI=10.1093/jnci/djq279;
RA   Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.;
RT   "Lung cancer cell lines as tools for biomedical discovery and
RT   research.";
RL   J. Natl. Cancer Inst. 102:1310-1321(2010).
//
RX   PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112;
RA   Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P.,
RA   Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F.,
RA   Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J.,
RA   Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L.,
RA   Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D.,
RA   Heymach J.V.;
RT   "Proteomic profiling identifies dysregulated pathways in small cell
RT   lung cancer and novel therapeutic targets including PARP1.";
RL   Cancer Discov. 2:798-811(2012).
//
RX   PubMed=26202522; DOI=10.1021/acs.jproteome.5b00477;
RA   Kitata R.B., Dimayacyac-Esleta B.R.T., Choong W.-K., Tsai C.-F.,
RA   Lin T.-D., Tsou C.-C., Weng S.-H., Chen Y.-J., Yang P.-C., Arco S.D.,
RA   Nesvizhskii A.I., Sung T.-Y., Chen Y.-J.;
RT   "Mining missing membrane proteins by high-pH reverse-phase stagetip
RT   fractionation and multiple reaction monitoring mass spectrometry.";
RL   J. Proteome Res. 14:3658-3669(2015).
//
RX   PubMed=26361996; DOI=10.1016/j.jprot.2015.09.003;
RA   Grundner-Culemann K., Dybowski J.N., Klammer M., Tebbe A., Schaab C.,
RA   Daub H.;
RT   "Comparative proteome analysis across non-small cell lung cancer cell
RT   lines.";
RL   J. Proteomics 130:1-10(2016).
//
RX   PubMed=26554430; DOI=10.1021/acs.analchem.5b03639;
RA   Dimayacyac-Esleta B.R.T., Tsai C.-F., Kitata R.B., Lin P.-Y., Choong W.-K.,
RA   Lin T.-D., Wang Y.-T., Weng S.-H., Yang P.-C., Arco S.D., Sung T.-Y.,
RA   Chen Y.-J.;
RT   "Rapid high-pH reverse phase stagetip for sensitive small-scale
RT   membrane proteomic profiling.";
RL   Anal. Chem. 87:12016-12023(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//